Tumor angiogenesis: diagnostic and therapeutic strategies.
DOI:
https://doi.org/10.35954/SM2012.31.1.5Keywords:
Tumor Angiogenesis; Angiogenesis Inhibitors; VEGF.Abstract
Angiogenesis is fundamental for tumor development, and the period during which the transition from the avascular tumor phase to the vascular phase occurs is regulated by the expression of pro-angiogenic factors such as vascular endothelial growth factor (VEGF). This substance is a glycoprotein that is produced by both normal and neoplastic cells and plays a very important role in both physiological and pathological situations. The binding of VEGF to its receptors leads to the recruitment of intracellular molecular signals responsible for cell survival, vascular permeability, migration and proliferation. Many studies have described the relationship between VEGF expression and patient prognosis in oncologic pathologies. Both VEGF and its receptors have been targets for the development of numerous therapeutic and diagnostic agents. In the present work we describe some of these agents, as well as their strategies and/or mechanisms to visualize or inhibit tumor angiogenesis.
Received for review: June 2012.
Accepted for publication: August 2012.
Downloads
Metrics
References
(1) Dvorak HF. Angiogenesis update 2005. Thromb Haemost 2005; 3:1835-1842.
(2) Ferrara N, Gerber HP, LeCounter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669-676.
(3) Hunter J. Lectures on the Principles of Surgery in the Works of John Hunter, ed. J. F. Palmer, vol.1, p.220. London : Longman, sf. p 220.
(4) Virchow R, Die. Krankhaften Geschwulste. Berlin : August Hirschwald, 1863.
(5) Goldman E. The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet 1907; 2:1236-40.
(6) Clark ER, et al. General observations on the ingrowth of new blood vessels into standardized chambers in the rabbit’s ear, and the subsequent changes in the newly grown vessels over a period of months. Anat Rec 1931; 50:129-67.
(7) Clark ER, Clark EI. Microscopic observations on the growth of blood capillaries in the living mammals. Am J Anat 1939; 64:251-301.
(8) Ide AG, Baker NH, Warren, et al. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol 1939; 32:891-9.
(9) Algire GH, Chalkley HW. Vascular reactions of normal and malignant tissue in vivo. J Natl Cancer Inst 1945; 6:73-85.
(10) Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285:1182–1186.
(11) Figg WD, Folkman J. Angiogenesis: an integrative approach from science to medicine. New York: Springer, 2008.
(12) Folkman J. Angiogenesis research: from laboratory to clinic. Forum (Geneva) 1999; 9:3 (3 Suppl):59-62.
(13) Dvorak HF, et al. Vascular permeability factor/ vascular endothelial growth factor and the significance on microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Inmunol 1999; 237:97-132.
(14) Shibuya M. Structure and fuction of VEGF/VEGF- receptor system involved in angiogenesis. Cell Struct Funct 2001; 26:25-35.
(15) Partanen TA, Paavonen K. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech 2001; 55:108-121.
(16) Houck KA, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5:1806-1814.
(17) De Vries C, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
(18) Veikkola T, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60:203-212.
(19) Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005; 9:209-31.
(20) Holash J, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284:1994-8.
(21) Ruhrberg C. Endogenous inhibitors of angiogenesis. J Cell Sci 2001; 114:3215-6.
(22) Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175:409-16.
(23) Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4- 6.
(24) Carmeliet P; Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57.
(25) Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 2004; 8:294- 300.
(26) Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorogenesis. Cell 1996; 86:353-64.
(27) Folkman J, et al. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001; 86:23-33.
(28) Moeller BJ, et al. The relationship between hypoxia and angiogenesis. Semin Radiat Oncol 2004;14:215-21.
(29) Semenza G. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003; 54:17-28.
(30) Goodsell D. The molecular perspective: VEGF and angiogenesis. Stem Cells 2003; 21: 118-119.
(31) Zetter B. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49:407-424.
(32) Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-36.
(33) Risau W. Mechanism of angiogenesis. Nature 1997; 386:671-74.
(34) Ferrara N. Role of vascular endothelial growth factor in physiologic and patholgic angiogenesis: therapeutic implications. Semin Oncol 2002; 29(6):10-14.
(35) Dvorak HF, Rons-Whipple A. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747- 57.
(36) Folkman J. Fundamental concepts of the angiogenesis process. Curr Mol Med 2003, 3: 643-51.
(37) Ingber D, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348:555-7.
(38) Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
(39) Hida K, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64:8249-55.
(40) Yu JL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295:1526-8.
(41) Ferrara N, Kerbel R. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
(42) Ferrando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. The Oncologist 2004; 9(1): 11-18.
(43) Presta LG, et al. Humanization of an anti-vascular endotelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-99.
(44) Lee CG, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60:5565-70.
(45) Prewett M, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-18.
(46) Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet- derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9(1):327-37.
(47) Wood JM, et al. PTK787/ ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-89.
(48) Pietras R, Weinberg O. Antiangiogenic Steroids in Human Cancer Therapy. ECAM 2005; 2(1): 49–57.
(49) Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002; 23(12): 576-82.
(50) Zhu Z, Witte L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs 1999; 17: 195-212.
(51) Weissleder R, Mahmood U. Molecular Imaging. Radiology 2001; 219:316- 33.
(52) Blankenberg FG, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci 1998; 95:6349–54.
(53) Miles K A. Perfusion CT for the assessment of tumour vascularity: which protocol? British Journal of Radiology 2003; 76: 36-42.
(54) Maria Moresco R, et al. PET in psychopharmacology. Pharmacol Res 2001; 44:151–9.
(55) Eleta F, et al. Imágenes moleculares: morfología y función. Rev Argent Radiol 2004; 68: 201-22.
(56) Cai W, et al. Positron emission tomography imaging of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47 (12): 2048-56.
(57) Cornelissen B, et al. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol 2005; 32:431–6.
(58) Cornelissen B, et al. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol 2005; 32:431–6.
(59) Jayson GC, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Nat Cancer Inst 2002; 94:1484–93.
(60) Goncalves M, et al. Design, synthesis, and evaluation of original carriers for targeting vascular endothelial growth factor receptor interactions. Pharm Res 2005; 22:1411–21.
(61) Camacho X, et al. [99mTc(CO)3]-Radiolabeled Bevacizumab: In vitro and in vivo evaluation in a Melanoma model. Oncology, “in press”; DOI: 10.1159/000338961.
(62) Janssen ML, et al. Tumor targeting with radiolabeled avh3 integrin binding peptides in a nude mouse model. Cancer Res 2002; 62:6146–51.
(63) Line BR, et al. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 2005; 46:1552–60.
(64) Haubner R, et al. Noninvasive imaging of avh3 integrin expression using 18F-labeled RGD-containing glycopeptides and positron emission tomography. Cancer Res 2001; 61:1781–5.
(65) Chen X, et al. MicroPET and autoradiographic imaging of breast cancer av-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 2004;15:41–9
(66) Chen X, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor avh3-integrin expression. J Nucl Med 2004; 45:1776–83.
(67) Cai W, et al. In vitro and in vivo characterization of 64Cu-labeled Abegrin2, a humanized monoclonal antibody against integrin αvβ3. Cancer Res 2006; 66:9673–81.
(68) Furumoto S, et al. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 2003; 30:119–25.
(69) Giersing BK, et al. Synthesis and characterization of 111In-DTPA-N-TIMP-2: a radiopharmaceutical for imaging matrix metalloproteinase expression. Bioconjug Chem 2001; 12:964–71.
(70) Oltenfreiter R, et al. New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents. Nucl Med Biol 2004; 31:459–68.
(71) Sprague JE, et al. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl Med Biol 2006; 33:227–37.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
